Copyright
©The Author(s) 2022.
World J Gastroenterol. Jun 7, 2022; 28(21): 2302-2319
Published online Jun 7, 2022. doi: 10.3748/wjg.v28.i21.2302
Published online Jun 7, 2022. doi: 10.3748/wjg.v28.i21.2302
Figure 6 Oesophageal adenocarcinoma patient’s tumour conditioned media were screened by multiplex immunosorbent assay kit.
The inhibitory checkpoints PD-1 and its ligand PD-L1, TIGT, TIM3, immunosuppressive molecule and checkpoint CD276 (B7-H3) and costimulatory molecule CD28 significantly decrease with fractionated radiotherapy (n = 8). A: PD-1; B: PD-L1; C: TIM-3; D: TIGIT; E: CD276; F: CD28. aP < 0.05 by Wilcoxon signed rank test.
- Citation: Donlon NE, Davern M, O’Connell F, Sheppard A, Heeran A, Bhardwaj A, Butler C, Narayanasamy R, Donohoe C, Phelan JJ, Lynam-Lennon N, Dunne MR, Maher S, O’Sullivan J, Reynolds JV, Lysaght J. Impact of radiotherapy on the immune landscape in oesophageal adenocarcinoma. World J Gastroenterol 2022; 28(21): 2302-2319
- URL: https://www.wjgnet.com/1007-9327/full/v28/i21/2302.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i21.2302